JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Enables N26 to Become Germany’s first Digital Bank to offer eSIM Mobile Plans13.5.2025 15:30:00 EEST | Press release
In a move set to reshape the intersection of fintech and telecom, 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. This partnership will grant N26’s German customers seamless access to flexible, affordable, and contract-free mobile connectivity—all activated directly through the N26 app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513954446/en/ 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. By integrating 1GLOBAL’s cutting-edge API, N26 has unlocked a frictionless mobile experience that eliminates the need for physical SIM cards, lengthy contracts, or cumbersome paperwork. Customers can activate their mobile plans in a few taps, enjoying instant connectivity that mi
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 15:05:00 EEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%13.5.2025 15:00:00 EEST | Press release
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT). The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that ongoing, effective training leads to lasting behavior change and a substantial reduction in vulnerability to cybersecurity threats. This highlights the critic
Armis Announces New Global Technology Integration Partners to Bolster Organizations’ Cyber Resilience13.5.2025 15:00:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has added 10 global technology integration partners over the past quarter. These integrations increase the functionality and efficiency of organizations’ existing technology stacks with added benefits from Armis’ platform and solutions. “Relying on siloed security solutions is no longer enough to gain a comprehensive, real-time understanding of an organization’s attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “Integrating Armis’ best-in-class platform with other leading vendors’ offerings empowers businesses to consolidate their technology stacks. By driving greater value in their security investments, organizations can ensure their entire attack surface is continuously defended and managed.” New Armis global technology integration partners include AnzenOT, Brinqa, ColorTokens, EasyVista, SaltyCloud, Salvador Tech, SIGA, Spectro Cloud, Stellar Cyber, and Synqly. From compliance to network
Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust13.5.2025 14:35:00 EEST | Press release
Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty. Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital. Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center. Kyriba’s approach directly addresses the "Trust Gap" – the growing divide between the pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom